The city of Boston, Massachusetts, currently has 478 active clinical trials seeking participants for Cancer research studies.
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
Recruiting
The Study is a Phase 3, randomized, three-arm, double-blind, placebo-controlled, multi-regional clinical research study to evaluate the safety and efficacy use of toripalimab alone or in combination with tifcemalimab as consolidation therapy in patients with limited-stage small cell lung cancer without disease progression following chemoradiotherapy. Tifcemalimab is a monoclonal antibody against B and T lymphocyte attenuator (BTLA). Toripalimab is a monoclonal antibody against programmed death... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: Dana Farber Cancer Institute-Hematology/Oncology, Boston, Massachusetts
Conditions: Limited-stage Small Cell Lung Cancer (LS-SCLC)
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
Recruiting
The goal of this study is to determine whether a palliative care intervention (PEACE) can improve the quality of life and experiences of participants with Lymphoma, Leukemia, or Multiple Myeloma receiving adoptive cellular therapy (ACT). After completion of an open pilot, participants will be randomly assigned into one of two study intervention groups. The names of the study intervention groups involved in this study are: * Palliative care (PEACE) plus usual oncology care * Usual care (standar... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Hematologic Malignancy, Blood Cancer, Lymphoma, Leukemia, Multiple Myeloma
Multisite Implementation of COMPRENDO
Recruiting
COMPRENDO (ChildhOod Malignancy Peer Research NavigatiOn) is a multi-site randomized clinical trial (RCT) that uses a Hybrid Type 1 design, to test the effects of a clinical intervention on patient-level outcomes, while exploring multilevel implementation factors that can inform real-world setting implementation. This study will test the impact of COMPRENDO, a peer-navigation intervention, vs. usual care on accrual to childhood cancer therapeutic clinical trials and parental informed consent out... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2024
Locations: Dana Farber Cancer Institute/Boston Children's Hospital, Boston, Massachusetts
Conditions: Pediatric Cancer
Circulating Tumor Cell Analysis in Patients With Localized Prostate Cancer Undergoing Prostatectomy
Recruiting
This study will evaluate a method to detect tumor cells that are circulating in the blood without getting a biopsy. The investigators already know from other studies that cancer tumors shed a small number of cells into the bloodstream every day. These are called circulating tumor cells (CTCs). Some early studies indicate the amount and type of CTCs in the blood can help determine the status of the tumor itself and the way it is responding to treatment. In this study, the investigators will compa... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/21/2024
Locations: Massachsuetts General Hospital, Boston, Massachusetts
Conditions: Prostate Cancer
REFLECTION: A Clinical Practice Learning Program for Galleri®
Recruiting
REFLECTION is a multi-center, prospective, non-interventional, cohort study that will enroll approximately 17,000 individuals who have opted to be screened with Galleri®, a blood-based, multi-cancer early detection (MCED) test in routine clinical settings. The purpose of the study is to understand the real-world experience of Galleri® in clinical settings.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
05/17/2024
Locations: Boston VA Research Institute (VA Boston), Boston, Massachusetts
Conditions: Early Detection of Cancer, Cancer
Polygenic Risk Stratification Combined With mpMRI to Identify Clinically Relevant Prostate Cancer
Recruiting
The goal of this clinical trial is to evaluate a screening method to detect clinically relevant prostate cancer. This clinical trial is using genetic data to determine a man's risk of cancer, together with multiparametric magnetic resonance imaging (mpMRI) to identify men with higher grade cancer. The main questions it aims to answer are: * If genetic data related to prostate cancer used with MRI can identify higher-grade, potentially fatal prostate cancer * What age a MRI is useful clinically... Read More
Gender:
MALE
Ages:
Between 40 years and 69 years
Trial Updated:
05/13/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Prostate Cancer, Polygenic Risk Score
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
Recruiting
This research is studying a new investigative imaging instrument called a nonlinear microscope (NLM). A nonlinear microscope can produce images similar to an ordinary pathologist's microscope, but without first processing tissue to make slides. This study will determine if a NLM can be used to evaluate tissue during lumpectomy surgery for breast cancer in order to reduce the probability that standard pathologic examination of the specimen after the end of the operation will find close or positiv... Read More
Gender:
FEMALE
Ages:
21 years and above
Trial Updated:
05/07/2024
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Breast Cancer
Testing Conversation Aid in Practice
Recruiting
The goal of this research study is to develop and test a website to help primary care providers (PCPs) discuss the pros and cons of mammography with women aged 75 and older and to help participants make decisions about mammography.
Gender:
FEMALE
Ages:
Between 75 years and 89 years
Trial Updated:
05/07/2024
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Breast Cancer
Ribociclib (LEE011) Rollover Study for Continued Access
Recruiting
This study is to allow continued use of ribociclib (LEE011) as single agent or in combination with other investigational treatments in patients benefitting from treatment in an eligible Novartis-sponsored ribociclib (LEE011) study that has reached its primary objective(s) or has been halted for other reasons.
Gender:
ALL
Ages:
80 years and below
Trial Updated:
04/25/2024
Locations: Dana Farber Cancer Institute Main Site, Boston, Massachusetts
Conditions: Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies
MyVHL: Patient Natural History Study
Recruiting
MyVHL is a multi-patient database which helps researchers identify patterns across VHL patients. MyVHL provides you -and researchers -with more complete information about VHL, like how your lifestyle, medications, and other factors impact the disease and quality of life. These insights help you better understand the condition and help researchers know where to focus their efforts. Due to its rarity, there is less understanding of VHL and the factors that may have an impact. The data individuals... Read More
Gender:
ALL
Ages:
All
Trial Updated:
04/25/2024
Locations: VHL Alliance, Boston, Massachusetts
Conditions: Von Hippel-Lindau Disease, Hereditary Leiomyomatosis and Renal Cell Cancer, Birt-Hogg-Dube Syndrome, SDHB Gene Mutation
TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
Recruiting
The aim of the project is to evaluate the risk-reducing salpingectomy with delayed oophorectomy as an alternative for risk-reducing salpingo-oophorectomy in high risk women with respect to ovarian cancer incidence.
Gender:
FEMALE
Ages:
Between 25 years and 50 years
Trial Updated:
04/15/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: BRCA1 Gene Mutation, BRCA2 Gene Mutation, RAD51C Gene Mutation, RAD51D Gene Mutation, BRIP1 Gene Mutation, Ovarian Cancer
Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma
Recruiting
This research study is examining the effectiveness of pembrolizumab plus cryoablation or aveluma plus cryoablation on people with urothelial carcinoma, including bladder cancer, that has spread.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/12/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts +1 locations
Conditions: Metastatic Urothelial Carcinoma, Bladder Cancer